AI Portfolio Summary
In 2025 Q4, Affinity Asset Advisors, LLC maintained a portfolio of 125 distinct positions. The most significant new addition to the portfolio was SPDR SERIES TRUST, which now represents 10.42% of the total fund value. The fund also reduced its exposure to MADRIGAL PHARMACEUTI by 72.9%.
Total Positions
125
Quarter
2025 Q4
Top Holding
XBI (10.4%)
Top 10 Concentration
43.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 125
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 10.42% | — |
#1
Prev: #—
|
9.5 | 1,500,000 | no change |
NEW
|
1,500,000 | $182,895,000 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 5.31% | 4.06% |
#2
4
Prev: #6
|
5.6 | 61,500 | 5.2% |
P
S
|
1,234,926 | $93,212,214 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 4.46% | 5.65% |
#3
1
Prev: #2
|
3.8 | no change | no change |
P
S
|
450,000 | $78,318,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 3.88% | 2.66% |
#4
6
Prev: #10
|
4.6 | 145,000 | 40.3% |
P
S
|
505,000 | $68,101,775 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IBB
CALL
ISHARES TR
|
CALL Option | 3.85% | — |
#5
Prev: #—
|
5.5 | 400,000 | no change |
NEW
|
400,000 | $67,508,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
VENTYX BIOSCIEN...
|
Healthcare | 3.34% | 1.06% |
#6
24
Prev: #30
|
4.3 | 2,560,143 | 65.2% |
P
S
|
6,484,558 | $58,555,559 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 3.19% | 4.90% |
#7
3
Prev: #4
|
1.8 | -150,000 | -10.7% |
P
S
|
1,250,000 | $56,025,000 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 3.11% | — |
#8
Prev: #—
|
4.7 | 185,000 | no change |
NEW
|
185,000 | $54,526,900 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 2.90% | 1.68% |
#9
11
Prev: #20
|
4.2 | 450,000 | 128.6% |
P
S
|
800,000 | $50,832,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 2.67% | 2.07% |
#10
8
Prev: #18
|
1.6 | 13,292 | 0.9% |
P
S
|
1,432,591 | $46,931,681 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
WAVE LIFE SCIEN...
|
Healthcare | 2.62% | 1.34% |
#11
12
Prev: #23
|
3.5 | 600,000 | 28.6% |
P
S
|
2,700,000 | $45,900,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMGN
CALL
AMGEN INC
|
CALL Option | 2.52% | — |
#12
Prev: #—
|
4.5 | 135,000 | no change |
NEW
|
135,000 | $44,186,850 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 2.49% | 2.46% |
#13
Prev: #13
|
2.0 | no change | no change |
P
S
|
1,400,000 | $43,694,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XLV
CALL
SELECT SECTOR S...
|
CALL Option | 2.21% | — |
#14
Prev: #—
|
4.4 | 250,000 | no change |
NEW
|
250,000 | $38,700,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 2.10% | 1.05% |
#15
16
Prev: #31
|
3.8 | 900,000 | 112.5% |
P
S
|
1,700,000 | $36,890,000 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 1.95% | 3.58% |
#16
9
Prev: #7
|
1.3 | 23,725 | 4.7% |
P
S
|
523,725 | $34,146,870 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVL
NUVALENT INC
|
Healthcare | 1.85% | 2.90% |
#17
8
Prev: #9
|
1.2 | -61,784 | -16.1% |
P
S
|
322,633 | $32,453,653 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 1.81% | 2.24% |
#18
2
Prev: #16
|
1.2 | -670,527 | -17.3% |
P
S
|
3,200,000 | $31,776,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.59% | 3.27% |
#19
11
Prev: #8
|
0.6 | -250,000 | -20.0% |
P
S
|
1,000,000 | $27,980,000 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FBRX
FORTE BIOSCIENC...
|
Healthcare | 1.54% | — |
#20
Prev: #—
|
4.1 | 989,490 | no change |
NEW
|
989,490 | $26,983,392 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.53% | 2.23% |
#21
4
Prev: #17
|
0.6 | -649,828 | -23.2% |
P
S
|
2,150,172 | $26,920,153 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 1.51% | 2.48% |
#22
10
Prev: #12
|
1.1 | -20,000 | -2.7% |
P
S
|
730,000 | $26,491,700 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 1.39% | 0.29% |
#23
39
Prev: #62
|
3.6 | 255,000 | 392.3% |
P
S
|
320,000 | $24,476,800 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.39% | 1.61% |
#24
3
Prev: #21
|
1.1 | -156,838 | -16.4% |
P
S
|
802,342 | $24,318,986 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 1.27% | — |
#25
Prev: #—
|
4.0 | 550,000 | no change |
NEW
|
550,000 | $22,220,000 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANAB
ANAPTYSBIO INC
|
Healthcare | 1.23% | — |
#26
Prev: #—
|
4.0 | 444,692 | no change |
NEW
|
444,692 | $21,558,668 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 1.14% | 0.14% |
#27
52
Prev: #79
|
3.5 | 1,668,289 | 632.4% |
P
S
|
1,932,106 | $19,997,297 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
OMEROS CORP
|
—
|
Bond/Debt | 1.10% | 0.41% |
#28
25
Prev: #53
|
2.4 | 1,000,000 | 18.1% |
P
S
|
6,525,000 | $19,383,995 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
QURE
CALL
UNIQURE NV
|
CALL Option | 1.09% | — |
#29
Prev: #—
|
3.9 | 800,000 | no change |
NEW
|
800,000 | $19,144,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 1.09% | 1.11% |
#30
3
Prev: #27
|
0.9 | 44,837 | 4.5% |
P
S
|
1,051,054 | $19,087,141 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 1.05% | 0.78% |
#31
5
Prev: #36
|
1.4 | no change | no change |
P
S
|
967,620 | $18,355,751 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 1.03% | 0.85% |
#32
2
Prev: #34
|
2.4 | 300,000 | 10.0% |
P
S
|
3,300,000 | $18,150,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 1.03% | 4.59% |
#33
28
Prev: #5
|
0.4 | -83,869 | -72.9% |
P
S
|
31,131 | $18,128,827 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.96% | 0.47% |
#34
16
Prev: #50
|
3.4 | 1,297,153 | 86.5% |
P
S
|
2,797,153 | $16,866,833 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.86% | 1.28% |
#35
11
Prev: #24
|
0.3 | -48,475 | -22.0% |
P
S
|
172,125 | $15,033,398 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.86% | 2.34% |
#36
21
Prev: #15
|
0.3 | -506,610 | -45.8% |
P
S
|
600,552 | $15,019,806 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ESTA
ESTABLISHMENT L...
|
Healthcare | 0.83% | 1.11% |
#37
9
Prev: #28
|
0.3 | -110,000 | -35.5% |
P
S
|
200,000 | $14,576,000 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
ERASCA INC
|
Healthcare | 0.83% | 0.81% |
#38
3
Prev: #35
|
0.8 | -385,787 | -9.0% |
P
S
|
3,900,000 | $14,508,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 0.72% | 0.77% |
#39
2
Prev: #37
|
0.8 | -53,330 | -17.6% |
P
S
|
250,000 | $12,660,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 0.71% | — |
#40
Prev: #—
|
3.8 | 350,000 | no change |
NEW
|
350,000 | $12,432,000 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 0.66% | 0.30% |
#41
20
Prev: #61
|
3.3 | 4,500,000 | 169.8% |
P
S
|
7,150,000 | $11,654,500 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TVTX
TRAVERE THERAPE...
|
Healthcare | 0.65% | 1.04% |
#42
10
Prev: #32
|
0.3 | -200,000 | -40.0% |
P
S
|
300,000 | $11,463,000 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 0.63% | 0.05% |
#43
45
Prev: #88
|
3.3 | 649,639 | 994.6% |
P
S
|
714,956 | $11,031,771 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
TRAVERE THERAPE...
|
—
|
Bond/Debt | 0.57% | 0.69% |
#44
5
Prev: #39
|
1.2 | no change | no change |
P
S
|
7,000,000 | $9,989,000 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 0.55% | 0.68% |
#45
5
Prev: #40
|
1.2 | no change | no change |
P
S
|
275,000 | $9,647,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.54% | 0.68% |
#46
5
Prev: #41
|
2.2 | 50,000 | 16.7% |
P
S
|
350,000 | $9,506,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 0.54% | 0.48% |
#47
1
Prev: #48
|
2.7 | 539,320 | 42.3% |
P
S
|
1,813,671 | $9,503,636 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 0.50% | — |
#48
Prev: #—
|
3.7 | 1,000,000 | no change |
NEW
|
1,000,000 | $8,860,000 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STRO
SUTRO BIOPHARMA...
|
Healthcare | 0.49% | 0.06% |
#49
38
Prev: #87
|
0.7 | -4,340 | -0.6% |
P
S
|
748,382 | $8,658,780 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 0.45% | 0.41% |
#50
4
Prev: #54
|
1.2 | no change | no change |
P
S
|
100,000 | $7,965,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 125 holdings